IN8bio to Present at the H.C. Wainwright Immune Cell Engager Virtual Conference
NEW YORK, Aug. 15, 2023 (GLOBE NEWSWIRE) — IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage…
News
Humacyte Presents Clinical Performance of Human Acellular Vessel™ (HAV™) From Ukrainian Humanitarian Program
-Clinical outcomes presented at Military Health System Research Symposium (MHSRS)- -Results will be included in…
Humacyte Presents Clinical Performance of Human Acellular Vessel™ (HAV™) From Ukrainian Humanitarian Program
-Clinical outcomes presented at Military Health System Research Symposium (MHSRS)- -Results will be included in…
Akari Therapeutics, Plc Announces ADS Ratio Change
NEW YORK and LONDON, Aug. 15, 2023 (GLOBE NEWSWIRE) — Akari Therapeutics, Plc (Nasdaq: AKTX),…
Akari Therapeutics, Plc Announces ADS Ratio Change
NEW YORK and LONDON, Aug. 15, 2023 (GLOBE NEWSWIRE) — Akari Therapeutics, Plc (Nasdaq: AKTX),…
Science 37 Recognized as Best Digital Health Solution Nominee at 2023 Prix Galien USA Awards
RESEARCH TRIANGLE PARK, N.C., Aug. 15, 2023 (GLOBE NEWSWIRE) — Science 37 Holdings, Inc. (Nasdaq:…
Science 37 Recognized as Best Digital Health Solution Nominee at 2023 Prix Galien USA Awards
RESEARCH TRIANGLE PARK, N.C., Aug. 15, 2023 (GLOBE NEWSWIRE) — Science 37 Holdings, Inc. (Nasdaq:…
60 Degrees Pharmaceuticals Registers ACLR8-LR, a Phase IIB Study of Tafenoquine for Treatment of COVID-19, on ClinicalTrials.gov
ACLR8-LR, a double-blind, randomized, placebo-controlled Phase IIB study to determine efficacy of the ARAKODA® regimen…
60 Degrees Pharmaceuticals Registers ACLR8-LR, a Phase IIB Study of Tafenoquine for Treatment of COVID-19, on ClinicalTrials.gov
ACLR8-LR, a double-blind, randomized, placebo-controlled Phase IIB study to determine efficacy of the ARAKODA® regimen…
Galecto Announces Topline Results from Phase 2b GALACTIC-1 Trial of GB0139 for the Treatment of Idiopathic Pulmonary Fibrosis
Announces next steps for clinical development plan in severe liver diseases BOSTON, Aug. 15, 2023…
Galecto Announces Topline Results from Phase 2b GALACTIC-1 Trial of GB0139 for the Treatment of Idiopathic Pulmonary Fibrosis
Announces next steps for clinical development plan in severe liver diseases BOSTON, Aug. 15, 2023…
Avicanna Reports Q2 2023 Financial Statement
TORONTO, Aug. 15, 2023 (GLOBE NEWSWIRE) — Avicanna Inc. (“Avicanna” or “Company “) (TSX: AVCN)…
Avicanna Reports Q2 2023 Financial Statement
TORONTO, Aug. 15, 2023 (GLOBE NEWSWIRE) — Avicanna Inc. (“Avicanna” or “Company “) (TSX: AVCN)…
Alterity Therapeutics Receives a $4.74 million Research & Development Tax Incentive Refund
MELBOURNE, Australia and SAN FRANCISCO, Aug. 15, 2023 (GLOBE NEWSWIRE) — Alterity Therapeutics Limited (ASX:…
Alterity Therapeutics Receives a $4.74 million Research & Development Tax Incentive Refund
MELBOURNE, Australia and SAN FRANCISCO, Aug. 15, 2023 (GLOBE NEWSWIRE) — Alterity Therapeutics Limited (ASX:…
Myriad Genetics Advances Prostate Cancer Care with Addition of Absolute Risk Reduction to Prolaris®
Prolaris is the only biomarker test to quantify the benefits of adding androgen deprivation therapy…
Myriad Genetics Advances Prostate Cancer Care with Addition of Absolute Risk Reduction to Prolaris®
Prolaris is the only biomarker test to quantify the benefits of adding androgen deprivation therapy…
Tiziana Life Sciences Announces FDA IND Clearance of Intranasal Foralumab for the Treatment of Alzheimer’s Disease
Foralumab to advance into Phase 2 human clinical trials using the world’s only fully human…
Tiziana Life Sciences Announces FDA IND Clearance of Intranasal Foralumab for the Treatment of Alzheimer’s Disease
Foralumab to advance into Phase 2 human clinical trials using the world’s only fully human…
Parexel and Partex Announce Innovative Alliance Leveraging Artificial Intelligence and Big Data to Accelerate Drug Discovery and Development
Collaboration combines clinical research expertise with artificial intelligence capabilities to help drug developers better understand…